Jutta Monika Heim
Chairman at Synendos Therapeutics AG
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Adesh Kaul | M | 50 | 15 years | |
Andrea Chicca | M | - |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | 5 years |
Gottlieb A. Keller | M | 70 |
University of Basel
| 6 years |
Rasmus Toft-Kehler | M | - |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | - |
Morten Otto Sommer | M | 43 |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | - |
Søren Lemonius | M | 59 |
Nuevolution A/S
Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark.
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | 13 years |
Stig Lökke Pedersen | M | 62 |
AntibioTx ApS
AntibioTx ApS Pharmaceuticals: MajorHealth Technology AntibioTx ApS develops and manufactures pharmaceutical products. The private company is based in Kongens Lyngby, Denmark.
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | - |
Paul Herrling | M | 78 |
University of Basel
| - |
Simon T. Russell | M | - |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | 5 years |
Beat Oberlin | M | 69 |
University of Basel
| 6 years |
Arthur Higgins | M | 68 |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | 3 years |
Verena A. Briner | M | 72 |
University of Basel
| - |
Roland Weiger | M | 63 |
University of Basel
| 22 years |
Marcel Tanner | M | - |
University of Basel
| - |
Bettina Ernst | M | - |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | - |
Jacqueline Henn Overbeck | M | 64 |
University of Basel
| 20 years |
Alan Tyndall | M | 76 |
University of Basel
| 33 years |
Ursula Eberhardt | F | 62 | 18 years | |
David Leppert | M | 66 |
University of Basel
| - |
Kim Domela Kjoeller | M | - |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | 3 years |
Tore von Würden Petersen | M | - |
Nuevolution A/S
Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | 5 years |
Barbara Kessler | M | - |
University of Basel
| - |
Henner Schierenbeck | M | 78 |
University of Basel
| 34 years |
Peter Meier-Abt | M | - |
University of Basel
| - |
Hansje Güntherodt | M | - |
University of Basel
| - |
John Martin Manser | M | 77 |
University of Basel
| - |
Tuomas Waltimo | M | 53 |
University of Basel
| - |
Raúl Martín Ruiz | M | - |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | - |
Peter Neubeck | M | - |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | - |
Martin Gertsch | M | 59 |
University of Basel
| - |
Reto Francioni | M | 68 |
University of Basel
| 18 years |
Fritz Melchers | M | - |
University of Basel
| - |
Barbara Anna Heller | F | 56 |
University of Basel
| 18 years |
Andrew Oakley | M | 62 |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | - |
Gitte Pugholm Aabo | F | 57 |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | - |
Thomas D. Szucs | M | 64 |
University of Basel
| - |
Morten Kjærgaard Jakobsen | M | - |
Nuevolution A/S
Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steven Skolsky | M | 68 | 15 years | |
Claude Schreiner | M | 82 | 6 years | |
Günter von Au | M | 73 |
Eberhard Karls Universität Tübingen
| 7 years |
Jessica Mann | M | - |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | 1 years |
Karin Erhard | F | 63 |
Eberhard Karls Universität Tübingen
| 7 years |
Reiner Strecker | M | 63 |
Eberhard Karls Universität Tübingen
| 4 years |
Hans-Christian Rohde | M | 67 | 5 years | |
Dieter Goette | M | - | 2 years | |
Rainer Kirchdörfer | M | 66 |
Eberhard Karls Universität Tübingen
| 5 years |
Bernhard Beck | M | 70 |
Eberhard Karls Universität Tübingen
| 4 years |
Dimitis Tzouganatos | M | 71 |
Eberhard Karls Universität Tübingen
| 3 years |
Ben T. G. Tan | M | - |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | 2 years |
Albrecht Merz | M | 69 |
Eberhard Karls Universität Tübingen
| 6 years |
Theodor Weimer | M | 65 |
Eberhard Karls Universität Tübingen
| 6 years |
Wolfgang Mutter | M | - |
Eberhard Karls Universität Tübingen
| 3 years |
Fritz Oesterle | M | 72 |
Eberhard Karls Universität Tübingen
| 2 years |
Cédric Ripert | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 35 | 64.81% |
Denmark | 10 | 18.52% |
Germany | 10 | 18.52% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jutta Monika Heim
- Personal Network